ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerBusiness Wire • 04/23/24
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyBusiness Wire • 03/06/24
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyBusiness Wire • 03/05/24
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialBusiness Wire • 02/21/24
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGBusiness Wire • 02/05/24
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionBusiness Wire • 01/02/24
Here's Why ImmunityBio (IBRX) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/04/23
ImmunityBio (IBRX)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 11/27/23
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceBusiness Wire • 11/16/23
First Data for ImmunityBio's Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityBusiness Wire • 11/07/23
FDA Accepts ImmunityBio's BLA Resubmission as Complete and Sets New PDUFA DateBusiness Wire • 10/26/23
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituBusiness Wire • 10/23/23
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant EntitiesBusiness Wire • 09/11/23